1. Home /
  2. Drug Approvals

Drug Approvals

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences says Selonsertib, a new drug for treating NASH, a type of liver disease, failed Phase 3 trials.

Merck Is Named No. 1 Pharma Pick at Bank of America

Merck Is Named No. 1 Pharma Pick at Bank of America

Strong sales of key cancer treatment drug Keytruda are expected to continue to drive revenues and earnings.

Chart of the Day, Part 1: Canopy Growth Could Be Key to Constellation Long Term

Chart of the Day, Part 1: Canopy Growth Could Be Key to Constellation Long Term

Analysts have noted that the weed leader's momentum is set to burn higher moving forward.

Real Money Goes Behind the Scenes of the Budding Cannabis Industry

Real Money Goes Behind the Scenes of the Budding Cannabis Industry

In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.

Allergan Pulls Breast Implant Off European Markets Due to Cancer Risk

Allergan Pulls Breast Implant Off European Markets Due to Cancer Risk

Allergan's textured breast implants have been linked to a rare form of cancer.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer may have poked the bear.

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.

Jim Cramer Breaks Down the Market and What Could Come Next

Jim Cramer Breaks Down the Market and What Could Come Next

Jim Cramer takes a look at the market.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.